Autoimmunity & Inflammation
Psoriatic Arthritis
Where skin, joints, tendons and metabolism inflame together
Psoriatic arthritis is an inflammatory arthritis that develops in many people with psoriasis, affecting joints, the spine, the points where tendons attach to bone, and the nails. It is closely tied to obesity and cardiovascular disease, so treating it well protects much more than the joints.
Also known as: PsA
By the numbers
43%
higher cardiovascular disease risk in PsA
Source: Polachek et al., Arthritis Care Res 2017
Animated explainer
See it happen inside the body
Educational animation based on published research. It is not medical advice and does not replace care from your own clinician.
Whole-body impact
The spillover effect
Chronic inflammation rarely stays in one place. Tap any organ to see how this condition reaches beyond its starting point.
Skin
Most people have psoriasis plaques, often years before joint symptoms; scalp, nail and intergluteal psoriasis are associated with higher arthritis risk.
Nails
Pitting, ridging and lifting of the nail from its bed are common and reflect inflammation close to the nearby finger joint and enthesis.
Entheses
Enthesitis causes pain where tendons attach, such as the Achilles tendon and the sole of the foot, and is a core domain treated in EULAR recommendations.
Fingers and toes
Dactylitis, or 'sausage digit', is diffuse swelling of an entire finger or toe and is a hallmark of PsA.
Spine
Some people develop inflammatory back pain and sacroiliitis, overlapping with axial spondyloarthritis.
Eyes
Uveitis, an inflammation inside the eye that causes pain, redness and light sensitivity, is a recognized extra-musculoskeletal manifestation requiring urgent care.
Heart and metabolism
A meta-analysis found about 43% higher cardiovascular disease risk in PsA, including higher rates of heart attack and heart failure; obesity and metabolic syndrome are common companions.
The biology
How it works
Psoriatic arthritis is driven largely by the IL-23 and IL-17 pathway. Immune cells in the skin, gut and at entheses, the sites where tendons and ligaments anchor to bone, respond to mechanical stress and other triggers by producing IL-23. This stimulates T cells and innate lymphoid cells to release IL-17A and IL-17F, along with TNF, which inflame the enthesis, synovium and skin. Over time the disease can both erode bone and build abnormal new bone, which is why joints may be damaged and tendons may stiffen. Fat tissue adds to the inflammatory signal, linking excess weight to more severe disease and poorer treatment response. Because the skin, joints, eyes, gut and blood vessels share these pathways, PsA is considered one member of a broader family of immune-mediated diseases.
Healthspan
Why it matters for longevity
Psoriatic arthritis affects longevity mainly through cardiometabolic disease. A meta-analysis of 11 observational studies found that people with PsA had roughly 43% higher risk of cardiovascular disease, with higher risks of heart attack, cerebrovascular disease and heart failure than the general population. Obesity, metabolic syndrome and diabetes cluster with PsA, and EULAR emphasizes that management should take these comorbidities into account. Uncontrolled inflammation also leads to joint damage, disability and loss of activity, which feeds back into weight gain and cardiovascular risk. Treating PsA early, along with weight, blood pressure, lipids and glucose, is a practical strategy for preserving both mobility and healthspan.
The Four Quadrant Protocol™
How it connects across all four quadrants
Autoimmunity, metabolism, hormones and cellular health feed each other. This is why we treat the whole system, not one lab value.
Quadrant 02 Metabolic & Obesity Health
Fat tissue produces inflammatory signals that worsen PsA, and obesity and metabolic syndrome are highly prevalent in PsA and add to cardiovascular risk.
Quadrant 03 Hormonal Optimization
Insulin resistance and sex-hormone changes interact with inflammation; peri- and postmenopausal shifts can change body composition and symptom burden.
Quadrant 04 Regenerative & Cellular Health
PsA both erodes bone and forms abnormal new bone at entheses, so protecting tendon, cartilage and bone tissue is central to long-term function.
Research and longevity frontier
What science is testing now
Emerging therapies and active trials. Listed for education only. Many are not yet approved and are not offered as treatments here.
Bimekizumab (dual IL-17A and IL-17F blockade)
Phase 3 completed (BE OPTIMAL, NCT03895203)
In biologic-naive patients, blocking both IL-17A and IL-17F significantly improved joint, skin and enthesitis outcomes versus placebo at 16 weeks.
IL-23 and IL-17 pathway therapies
Approved classes; included in EULAR 2023 recommendations
EULAR 2023 positions IL-17 and IL-23 inhibitors alongside TNF inhibitors, with choice guided by skin, enthesis, spine and eye involvement.
Vitamin D and autoimmune prevention (VITAL)
Completed RCT (2022)
In older adults, vitamin D3 supplementation for five years was associated with fewer new autoimmune diagnoses overall, with psoriasis among the most common outcomes; this is a prevention signal, not a PsA treatment.
Common questions
Frequently asked
I have psoriasis. How do I know if it is becoming psoriatic arthritis?
Watch for joint swelling, morning stiffness, heel or Achilles pain, a swollen 'sausage' finger or toe, or inflammatory back pain. Nail changes and scalp psoriasis are linked to higher risk, so mention any of these to your clinician early.
Why does weight matter so much in PsA?
Fat tissue releases inflammatory signals that add to PsA activity, and obesity is linked to more severe disease and poorer treatment response. Metabolic health is also the main driver of cardiovascular risk in PsA.
Is psoriatic arthritis linked to heart disease?
Yes. A meta-analysis found about 43% higher cardiovascular disease risk in people with PsA. EULAR recommends regular cardiovascular risk assessment in inflammatory arthritis.
Peer-reviewed sources
Published evidence
Every claim on this page is drawn from peer-reviewed research, guidelines and registered clinical trials. Open any source to read the original.
guideline
Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83:706-719.
meta-analysis
Polachek A, Touma Z, Anderson M, Eder L. Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies. Arthritis Care Res. 2017;69:67-74.
RCT
McInnes IB, Asahina A, Coates LC, et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet. 2023;401:25-37.
guideline
Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76:17-28.
RCT
Hahn J, Cook NR, Alexander EK, et al. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ. 2022;376:e066452.
trial-registry
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE OPTIMAL). ClinicalTrials.gov identifier NCT03895203.
Educational website
fourquadrantprotocol.com is an educational resource. Content summarizes published research for learning purposes only. It is not medical advice, diagnosis or treatment, and it does not create a doctor-patient relationship. Always talk with your own clinician before changing any treatment. Questions: info@fourquadrantprotocol.com
Ready to look at the whole picture?
Work with Dr. Faisal Tahir to map your own four quadrants.
Book a consultation